Cerus (NASDAQ:CERS) Issues Earnings Results, Beats Expectations By $0.02 EPS

Cerus (NASDAQ:CERS) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.02, FiscalAI reports. The business had revenue of $59.89 million for the quarter, compared to analysts’ expectations of $55.68 million. Cerus had a negative net margin of 7.58% and a negative return on equity of 26.09%.

Here are the key takeaways from Cerus’ conference call:

• Cerus raised full?year 2026 product revenue guidance to $227M–$231M and IFC revenue to $22M–$24M after Q1 product revenue of $53.7M, up 24% year?over?year driven by platelet strength and accelerating U.S. IFC demand.
• First?quarter gross margin declined to 52% (from 58.8% a year ago) and management now expects 2026 gross margin to remain in the low?50s due to persistent inflation, tariffs, and foreign?exchange headwinds.
• Non?GAAP adjusted EBITDA was positive $4M in Q1 (the eighth consecutive quarter), GAAP net loss narrowed to $1.6M, and the company ended the quarter with $80.4M in cash while noting a $3M operational cash use tied to inventory builds for growth.
• Near?term regulatory and product catalysts include a U.S. PMA submission for the INT100/INT200 this quarter (INT200 launch targeted in H1 2027) and a Phase III RedeS readout for the Red Blood Cell program in Q4 2026 with a likely CE?mark pathway into early 2027.
• Commercial momentum includes early traction from the BCA agreement (access to ~50% of U.S. blood supply), a multi?year renewal with France’s EFS, and an ongoing shift toward kit?based IFC sales that management expects will broaden reach and support margin expansion.

Cerus Stock Up 26.8%

Shares of Cerus stock traded up $0.55 during trading on Friday, hitting $2.58. The company’s stock had a trading volume of 18,746,461 shares, compared to its average volume of 1,742,218. Cerus has a 52 week low of $1.15 and a 52 week high of $3.15. The company has a market capitalization of $515.95 million, a PE ratio of -32.19 and a beta of 1.63. The company has a fifty day simple moving average of $1.97 and a two-hundred day simple moving average of $1.98. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.17 and a current ratio of 1.73.

Cerus News Roundup

Here are the key news stories impacting Cerus this week:

• Positive Sentiment: Q1 beat and improved profitability: Cerus reported revenue of $59.9M (?+22.6% YoY) and GAAP diluted EPS of -$0.01, both beating Street expectations; net loss and operating loss narrowed materially versus a year ago—this explains much of the bullish reaction. Cerus Q1 2026 Earnings Highlights
• Positive Sentiment: Stronger cash generation / balance sheet: operating cash flow was positive (~$6.2M) and cash & equivalents ended the quarter at ~$27.9M, reducing short-term runway risk and supporting the stock rally. QuiverQuant: Stock Rises on Q1 Earnings
• Positive Sentiment: Analyst upgrade: BTIG raised its rating from Neutral to Buy and set a $4.00 price target (roughly +53% vs recent levels), providing a fresh catalyst and institutional attention. BTIG Upgrade (coverage)
• Neutral Sentiment: Call/transcript availability: Management’s Q1 earnings call and full transcripts are posted (useful for reading guidance detail, margin drivers and commercial commentary). Seeking Alpha Call Transcript
• Negative Sentiment: FY-2026 revenue guidance came in below consensus: Cerus updated FY revenue guidance to $227.0M–$231.0M versus a consensus around $233.9M, which could temper upside expectations despite the quarter’s beat. MarketBeat: Earnings & Guidance
• Negative Sentiment: Significant insider selling noted: multiple senior executives sold shares over the past six months (no reported insider buys), a potential negative signal for some investors. QuiverQuant: Insider Activity

Analysts Set New Price Targets

CERS has been the topic of a number of research reports. BTIG Research raised shares of Cerus from a “neutral” rating to a “buy” rating and set a $4.00 target price on the stock in a research note on Friday. Zacks Research lowered shares of Cerus from a “hold” rating to a “strong sell” rating in a report on Thursday, March 12th. TD Cowen reiterated a “buy” rating on shares of Cerus in a report on Monday, January 12th. Wall Street Zen lowered Cerus from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cerus in a research note on Wednesday, March 25th. Two research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $4.00.

Insider Buying and Selling at Cerus

In other news, CFO Kevin Dennis Green sold 127,544 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $1.66, for a total value of $211,723.04. Following the sale, the chief financial officer directly owned 1,040,551 shares of the company’s stock, valued at $1,727,314.66. The trade was a 10.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Chrystal Jensen sold 30,845 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $2.01, for a total value of $61,998.45. Following the completion of the sale, the insider owned 1,059,139 shares in the company, valued at $2,128,869.39. The trade was a 2.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,194,282 shares of company stock valued at $2,106,290 over the last three months. 5.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Cerus

Institutional investors have recently made changes to their positions in the stock. Cibc World Markets Corp bought a new stake in shares of Cerus during the 4th quarter valued at about $25,000. MML Investors Services LLC bought a new position in shares of Cerus in the 4th quarter worth approximately $37,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Cerus by 68.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 18,712 shares of the biotechnology company’s stock worth $39,000 after buying an additional 7,603 shares during the last quarter. CIBC Bancorp USA Inc. bought a new stake in Cerus during the third quarter valued at approximately $31,000. Finally, Aquatic Capital Management LLC bought a new stake in Cerus during the third quarter valued at approximately $35,000. Hedge funds and other institutional investors own 78.37% of the company’s stock.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.